Conference Track

Update on Hepatitis B Management

Source: CCO Independent Conference Coverage of the 2008 Annual Meeting of the European Association for the Study of the Liver*

*CCO is an independent medical education company that provides state-of-the-art medical information to healthcare professionals through conference coverage and other educational programs.

Capsule Summaries

Rapid, Persistent HBV DNA Suppression With Tenofovir Treatment in HBeAg-Negative Chronic Hepatitis B
Continued Efficacy With Tenofovir Through Week 72 of Therapy in HBeAg-Positive Patients
Adefovir Resistance Predictive of Reduced Response to Tenofovir in Retrospective Analysis
Tenofovir Antiviral Activity Similar in Lamivudine-Naive and Lamivudine-Experienced Individuals With Chronic Hepatitis B
Similar Efficacy of Tenofovir vs Coformulated Tenofovir/Emtricitabine in HBV-Infected Patients With Persistent Viremia on Adefovir
Magnitude of HBsAg Decline on Treatment Predicts Posttreatment HBsAg Clearance Following Peginterferon alfa-2a–Based Therapy
Long-term HBV DNA Suppression With Adefovir/Lamivudine Combination in Chronic Hepatitis B Patients With Lamivudine Resistance
Long-term Entecavir Treatment Safe and Effective in Japanese Treatment-Naive Chronic Hepatitis B Patients Through Year 3
HBeAg Seroconversion Sustained for 52 Weeks in Chronic Hepatitis B Patients Treated With Telbivudine or Lamivudine Following Consolidation Therapy
Increasing Rates of Virologic Suppression Through Year 3 of Entecavir Treatment in Chinese Cohort With Lamivudine Resistance

Expert Analysis

Update on Hepatitis B Management

Faculty:

Kris V. Kowdley, MD, FACP, FACG, FASGE, AGAF
Patrick Marcellin, MD
Norah Terrault, MD, MPH

Learning Objectives

Upon completion of this activity, participants should be able to:

Discuss the efficacy and safety of first-line therapies for the treatment of patients with chronic hepatitis B virus infection
Recount strategies for predicting response and management of suboptimal response to hepatitis B virus therapy
Describe data concerning the prevalence of nucleos(t)ide resistance in hepatitis B virus patients and strategies to manage it

CME CREDIT INFORMATION

Release Date: 07/03/08

Expiration Date: 07/02/09

Physicians: maximum of 1.0 AMA PRA Category 1 Credit™

Registered Nurses: 1.0 Nursing CE credit

Pharmacists: 1.0 contact hour (0.1 CEUs)

Status: Please log in to view status

Disclaimer: The materials published on the Clinical Care Options Web site reflect the views of the reviewers or authors of the CCO material, not those of Clinical Care Options, LLC, the CME provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.